Remote Robotic Surgery for Gynecologic Cancer: A Safety and Effectiveness Study

This investigator-initiated, multicenter, single-blind, randomized controlled clinical study is designed to evaluate the safety and effectiveness of the MP2000 thoracoabdominal endoscopic surgical system (Shenzhen Jingfeng Medical Technology Co., Ltd.) when used for remote robotic surgery in patients with gynecologic malignancies. By comparing remote robotic surgery with local robotic surgery, the study will assess clinical outcomes including postoperative recovery, the incidence of complications, and the length of hospital stay, thereby providing clinical evidence on the safety and efficacy of remote robotic surgery versus conventional local robotic surgery.

Inclusion Criteria: Cervical cancer: aged 18 to 70 years; or endometrial cancer: aged 18 to 80 years. BMI: 18 to 40 kg/m². Histopathologically confirmed endometrial cancer or cervical cancer with an indication for surgery. Physiologically suitable for laparoscopic surgery. Willing to comply with and complete study follow-up and related examinations. Voluntary signing of the informed consent form. Exclusion Criteria: Severe cardiovascular or circulatory disease that makes surgery intolerable. Fertility-sparing requirement. Pregnancy or lactation. History of epilepsy or psychiatric disorders. Severe allergic constitution, or suspected or confirmed alcohol or drug addiction. Inability to understand study requirements or complete the follow-up schedule. Any other condition deemed unsuitable for participation by the investigator.